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 CURRENTOPINION Novel immunotherapy vaccine development
Marek Jutela,b and Cezmi A. Akdisc
Purpose of review
Allergen-specific immunotherapy is the only curative treatment for allergic diseases. In spite of the great
progress in both vaccine development and the methods of allergen immunotherapy (AIT) in recent years,
several key problems related to limited efficacy, side-effects, low patient adherence and the relatively high
costs due to the long duration (3–5 years) remain to be solved. The current approaches aiming at
optimization of AIT are reviewed, including both conceptual studies in experimental models and proof-of-
concept – as well as large, multicenter clinical studies.
Recent findings
The most promising approaches to improve efficacy and safety of vaccine-based AIT include bypassing IgE
binding and targeting allergen-specific T cells using hypoallergenic recombinant allergen derivatives and
immunogenic peptides, the use of new adjuvants and stimulators of the innate immune response, the fusion
of allergens to immune modifiers and peptide carrier proteins and new routes of vaccine administration.
Summary
The cloning of allergen proteins and genetic engineering enabled the production of vaccines that have well
defined molecular, immunologic and biologic characteristics as well as modified molecular structure. These
new compounds along with new immunization protocols can bring us closer to the ultimate goal of AIT,
that is, complete cure of a large number of allergic patients.
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INTRODUCTION
The advances in immunology and bioengineer-
ing provide a rationale for improvement of the
current allergen immunotherapy (AIT) methods
in the fields of both new vaccines and novel
methods, including new routes of application.
These new approaches should contribute to the
solving of the major problems of AIT, which
include poor selection and monitoring criteria, as
well as relatively high costs and the burden for the
patients related to the multiple visits and duration
of 3–5 years.
Major current approaches to develop more
efficacious and safer AIT vaccines are shown in
Table 1 [1–20,21
&&
,22–27,28
&&
,29,30].
BYPASSING IGE BINDING AND
TARGETING ALLERGEN-SPECIFIC T CELLS
Allergen fragments, fusions, hybrids and chimeras
[1,3–5,31,32] are used to avoid recognition by
conformation-dependent B-cell epitopes and utilize
linear amino acid sequence of T-cell epitopes.
These approaches provide the possibility to enhance
the tolerogenic T-cell-dependent signal due to the
administration of higher doses of preparation with
the low risk of anaphylaxis [11,32].
Especially, the application of peptides represent-
ing linear T-cell epitope peptides [33,34
&
,35
&
,36–39]
has been recently investigated in clinical trials
showing promising results. An interesting approach
relates to overlapping peptides of Bet v 1. A large
multicenter study [39] showed good clinical efficacy
in birch pollen-allergic patients with rhinitis.
THE USE OF RECOMBINANT ALLERGENS
AND THEIR MIXTURES
The first study [13] using a vaccine that contained
a mixture of five recombinant native grass pollen
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allergens showed efficacy in reducing symptom-
medication scores in patients with grass pollen-
induced allergic rhinitis. In addition, a strong
immune response to grass pollen allergens was dem-
onstrated by induction of high allergen-specific
IgG1 and IgG4 antibody specific to grass extract.
The treatment also showed a very good safety pro-
file. Clinical trials with recombinant allergen prep-
aration mainly for grass pollen, birch pollen and
house dust mites showed good clinical efficacy com-
pared with placebo.
The potential of hypoallergenic derivatives with
the most reduced IgE reactivity has been evaluated
in a mouse model for cat allergy and by skin tests on
cat-allergic patients [40]. A hypoallergenic folding
variant of themajor birch pollen allergen Bet v1 (Bet
v1-FV) was investigated in a dose-finding study
[41
&&
]. The optimal dose for specific immunotherapy
(SIT) was assessed using environmental exposure
chamber and the maintenance dose of 80mg of rBet
v 1-FV was found to be the most effective and well
tolerated.
However, it has to be noted that the indirect
comparison does not show significantly higher effi-
cacy of the currently tested recombinant preparation
as comparedwith the extracts. Thus, it is still difficult
to justify the high costs of vaccine development and
licensing until new studies appear [6].
VACCINE ADJUVANTS AND STIMULATORS
OF THE INNATE IMMUNE RESPONSE
The design of more powerful adjuvants might prove
to be easier and economically justified as compared
with new allergen-derived compounds. Detoxified
lipopolysaccharide (MPL-A), CpG oligonucleotides,
imidazoquinolines and adenine derivatives, which
activate innate immune response, are the most suit-
able candidates for allergy vaccination aiming at the
better induction of specific TH1 differentiation [42].
The time, intensity and tissue location of the
innate signal combinedwith specific allergen trigger
are basic to the activation of a tolerogenic immune
response triggered by activation of toll-like receptors
(TLRs). Interestingly, natural exposure to many
aeroallergens involves exposure to innate immune
response-stimulating substances that activate TLR-
4. In addition, allergens such as house dust mites
can themselves trigger TLR-4 in airway structural
cells [43].
Initial studies with ragweed antigen (Amb a 1)
bonded to TLR-9 agonist CpG showed promising
results in the treatment of allergic rhinitis in the
ragweed-allergic patients. However, a subsequent
larger multicenter trial failed to demonstrate signifi-
cant improvement in symptom scores in the treat-
ment group [14].
Novel research provides an enormous number of
immune stimulators andmethods for coupling with
allergens [15–19,44]; however, both proof of con-
cept and controlled, large clinical studies are still to
be performed.
THE FUSION OF ALLERGENS TO IMMUNE
MODIFIERS AND PEPTIDE CARRIER
FUSION PROTEINS
Major cat allergen Fel d 1 was cloned and expressed
together with HIV protein, TAT-derived membrane
translocation domain and a truncated peptide of the
invariant chain (modular antigen translocation-Fel
d 1) [45] in order to intensify allergen inter-
nalization and presentation to T cells by antigen-
presenting cells. This compound was tested in a first
recombinant cat allergen double-blind, placebo-
controlled clinical trial using the intranodal route.
The administration of only three increasing doses
(1mg, 3mg and 10mg) at 4-week intervals showed
good clinical efficacy assessed by nasal provocation
challenge, very high safety profile as well strong
immune response measured by increased concen-
trations of specific IgG4 in serum [27,28
&&
].
1,25-DihydrovitaminD3 has been shown to
increase regulatory T-cell responses by affecting
dendritic cells for their tolerogenic properties. In a
mousemodel for cat allergy, vaccine containing rFel
d 1 covalently coupled to VitD3 was tested [46],
showing superiority to rFel d 1 only.
Another approach represents allergen co-
valently coupled to carbohydrate-based particles
for targeting of dendritic cells and enhanced adju-
vanticity in SIT [47]. Promising data have been pro-
vided in studies in mouse model of cat allergy [48].
FcgRIIb is an immune tyrosine-based inhibitory
motif containing receptor65. The coaggregation of
FcgRI and FcgRIIb inhibits FcgRI signaling, so one
KEY POINTS
 Improvements of SIT are key to the progress in allergy
prevention and treatment.
 Research has been focused on new vaccine
formulations, which provide better efficacy and safety
mainly by bypassing IgE responses and targeting
T cells.
 Novel adjuvants, carrier proteins and new routes also
show promising insights.
 The application of the advanced vaccines is limited by
the high costs of clinical development.
Immunotherapy and new treatments
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strategy thathasbeen tested is the fusionofFcgRIIb to
allergens to down-regulate downstream allergen-
specific immune responses. In a similar approach,
the fusion of allergens to human Fcg suppressed
allergen-induced degranulation of basophils and
mast cells by cross-linking Fcg and FcgRI receptors
[25,26].
A carrier protein, the Pre-S domain of hepatitis B
virus, has been used by fusion to two nonallergenic
peptides of Fel d 1 or Bet v 1 [19,20,21
&&
]. This
approach eliminated both IgE-mediated and T-cell-
mediated side-effects. ThePre-Sdomainofhepatitis B
virus contains antigenic sites for both B and T cells
and provides T-cell help. Peptides derived from the
IgE-reactive areas of Bet v 1were fused to a hepatitis B
surface protein. This fusion peptide reduced T-cell
activation in vitro and induced allergen-specific IgG
in a rabbit model.
Similar results were provided by Chen et al.
[49,50] (using carrier-bound Der p 2 peptides or rDer
p 2/1 mosaic proteins).
COMBINATION WITH IMMUNE RESPONSE
MODIFIERS
The combination AIT and anti-IgE (omalizumab)
treatment has been investigated [36] in several trials.
A good safety profile, significant decrease in the risk
of anaphylaxis and improved rescue medication
scores were reported [29,30,51].
ROUTES OF VACCINE ADMINISTRATION
The efficacy of sublingual immunotherapy (SLIT) for
the treatmentof allergic rhinitis and asthmahas been
well established; however, the direct head-to-head
studies comparing SLIT and subcutaneous immuno-
therapy (SCIT) are lacking [52,53]. In addition, sus-
tained disease-modifying effects of SLIT have been
demonstrated in randomized, double-blind, placebo-
controlled trials in adults and in children [54,55]. The
immunologic mechanisms of SLIT are similar to
SCIT. They involve increased blocking IgG4, IgA
antibodies, activation of Treg cells, increased IL-10
production and increased numbers of sublingual
FOXP3-expressingTcells [56–58].However, themag-
nitude of the changes, especially increase in specific
IgG4 response, is rather modest. Future studies
should address this issue by using novel adjuvants
and increasing the effective doses of allergen.
Recently, sugar-modified antigens have been shown
to effectively induce oral tolerance. A C-type lectin
receptor, SIGNR-1 (CD209b), is capable of condition-
ing of dendritic cells to induce tolerance in gastro-
intestinal lamina propria in a model of food-
induced anaphylaxis [59]. rBet v 1a formulated in
amylopectin-based microparticles has also been
investigated in a mouse model [60].
Work is going on to use intralymphnode and
epicutaneous routesof vaccine application.Thedem-
onstrated advantage of these approaches involves
fewer doses, that is, patients’ visits at the office and
lower total dose of allergen required to achieve
clinical efficacy [22–24]. However, both indirect effi-
cacy comparisons show similar efficacy to SCIT in the
treatment of grass pollen allergy. Interestingly, intra-
lymphatic vaccines are capable of inducing strong
T-cell responses associated with cytotoxic activity
and IFN-g production, which are important in
long-term protection against viral infections.
CONCLUSION
In spite of the progress in improving the efficacy and
safety of AIT, there is still the great potential for
further modifications, which are hoped to broaden
the pool of candidates for AIT, aiming atmuch better
treatment and prevention of allergic diseases as well
as other diseases related to immune dysregulation.
However, the major barrier for the clinical applica-
tion of these new technologies is the capacity to
perform a large number of phase 3 confirmatory
double-blind, placebo-controlled clinical trials.
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